Clinical Trial Update: To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of intravitreal ranibizumab for vision loss due to macular edema has completed, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Macular Edema (ME) | Phase 3 | Status: COMPLETED | Results posted: 2016-05-23